Long term data from four open label lacosamide extension trials reported at the 29th International Epilepsy Congress New non-interventional study (VITOBA TM) aims to investigate additive or ...
-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking ...
ATLANTA, June 29, 2010 /EurekAlert!/ — New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment ...
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for the antiepileptic drug lacosamide (Vimpat, UCB) as monotherapy in treating partial-onset seizures in ...
Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...
Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy - Vimpat(R) demonstrated greater seizure ...
UCB today announced new findings from analyses of pooled Vimpat(r) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of ...
Use of lacosamide as the last antiepileptic drug (AED) a patient is administered for status epilepticus (SE) is "strongly associated with termination of status." VANCOUVER, BC—Use of lacosamide as the ...
Lacosamide 10mg/mL; strawberry-flavored; contains phenylalanine 0.32mg/20mL. See full labeling. Tabs: swallow whole. Oral soln: use calibrated measuring device. Injection: can give without diluting, ...
BRUSSELS, Belgium The Food and Drug Administration’s approval of UCB’s epilepsy drug Vimpat caused the drug maker’s shares to increase by almost 11 percent Wednesday. The FDA approved Vimpat ...
New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback